Dr. Raquel Rozdolski is a board-certified dentist anesthesiologist in New York who is also the Director of Anesthesia & Pain Control at Touro College of Dental Medicine. In 2020, Dr. Raquel Rozdolski published an article that provided guidelines for co-prescribing opioids and naloxone within the dental office.
Co-authored with Dr. Madeleine Maas, “Recommendations for Co-Prescription of Opioids and Naloxone in the Dental Office” appeared in volume 52, number 3 of Pulse, the official newsletter of the American Dental Society of Anesthesiology. In short, the article advocates for co-prescription as a way to fight opioid use disorder and prevent potential opioid overdoses. Although the Centers for Disease Control and Prevention recommends naloxone co-prescriptions only at a certain opioid prescription dosage level, “Recommendations for Co-Prescription of Opioids and Naloxone in the Dental Office” contends that dentists should also consider this approach for patients at high risk of opioid misuse, as identified by clinical screenings. The article also stresses the importance of patient education regarding both opioids and naloxone.
Co-authored with Dr. Madeleine Maas, “Recommendations for Co-Prescription of Opioids and Naloxone in the Dental Office” appeared in volume 52, number 3 of Pulse, the official newsletter of the American Dental Society of Anesthesiology. In short, the article advocates for co-prescription as a way to fight opioid use disorder and prevent potential opioid overdoses. Although the Centers for Disease Control and Prevention recommends naloxone co-prescriptions only at a certain opioid prescription dosage level, “Recommendations for Co-Prescription of Opioids and Naloxone in the Dental Office” contends that dentists should also consider this approach for patients at high risk of opioid misuse, as identified by clinical screenings. The article also stresses the importance of patient education regarding both opioids and naloxone.
